Biotech
Colossal Biosciences
Colossal Biosciences raises $200M Series C at $10.2B valuation
$200M
Total Raised
Series C
Latest Round
2021
Founded
150+
Employees
Dallas, TX
1 min read
Quick Facts
Valuation
$10.2B
Latest Round Size
$200M
Latest Round Date
February 2025
Colossal Biosciences: Series C Funding Round
Colossal Biosciences has successfully raised $200M in Series C funding, reaching a valuation of $10.2B.
Company Overview
De-extinction and genetic engineering
Funding Details
The Series C round was led by Breyer Capital, with participation from In-Q-Tel, Tony Robbins.
Company Information
- Headquarters: Dallas, TX
- Founded: 2021
- Employees: 150+
- Category: Biotech
Investment
Colossal Biosciences plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Breyer Capital: Verified investor in Series C
- In-Q-Tel: Verified investor in Series C
- Tony Robbins: Verified investor in Series C
Key Investors
Breyer Capital
Lead Investor
Verified investor in Series C
In-Q-Tel
Investor
Verified investor in Series C
Tony Robbins
Investor
Verified investor in Series C
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min readβ’$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min readβ’$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min readβ’$250M